Health economist warns about eternal patent-threat
If government requirements concerning the production of biosimilars become too stringent, patent expirations will have no effect. A health economist now voices his concern that it will have a huge impact on the development of new drugs and our overall economy.
It could be extremely costly and inhibiting to the development of new medicine, if the regulatory requirements for copies of biological medicine, also known as biosimilars, become too strict. The warning comes from health economist Jesper Nørregaard, following a recent seminar on biosimilars held by pharmaceutical company Roche.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
.jpg&w=384&q=75){kind=logo}
